In Great Britain, the first country in the world was approved on Monday for a vaccine that targets both the primary variant of the coronavirus and the variant of Omikron.
The UK Medicines and Health Products Regulatory Authority (MHRA) announced that Mr.Moderna product, containing 25 micrograms of the vaccine working against the original version and 25 micrograms of the vaccine developed for the Omikron variant, meets the standards of safety, quality and effectiveness.
Two-variant vaccine will be available in the fall as a booster dose. The Joint Committee on Vaccination and Immunization (JCVI) will decide who will be eligible. From September, all high-risk people over the age of 50 and younger will be able to receive some form of booster vaccination.
The vaccines used during the COVID-19 pandemic are designed to set the body to fight the original form of the virus that emerged in Wuhan, China at the end of 2019. But the coronavirus has mutated significantly since then, resulting in a host of new variants, some of which are more resistant to vaccines. They have caused large spikes in cases around the world.
The results of tests carried out on 437 people showed that in people who received the new version of the vaccine, the level of antibodies that could inactivate the original variant of Omikron (BA.1), as well as its later sub-variants (BA.4 and BA.5), which caused the current wave of illnesses in Great Britain.
Moderna has submitted a two-variant vaccine for approval also to regulators in the European Union, Australia and Canada. It is expected to be approved by the EU by September.
From London, Bartłomiej Niedziński
At medonetmarket.pl you will find home tests for SARS-CoV-2:
- COVID-19 Rapid Test – Antigenic Test for Self-Control
- COVID-19 antigen test – SGTi-flex COVID-19 Ag
- Home COVID-19 Ag SGTi-flex cartridge test
- COVID-19 – Rapid Saliva Antigen Test